NCT00626275View on ClinicalTrials.gov

Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Participants With Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Rheumatoid Arthritis
Interventions
DRUG

ADL5859

DRUG

Naproxen

DRUG

Placebo

DRUG

ADL5859

DRUG

Placebo

Trial Locations (8)

11501

Winthrop University Hospital, Clinical Trials Center, Mineola

20901

The Center for Rheumatology and Bone Research, Wheaton

32117

Covance Clinical Research Unit Inc., Daytona Beach

44122

University Hospitals Case Medical Center, Division of Rheumatology, Rheumatology Clinical Research Unit, Beachwood

68134

Heartland Clinical Research, Inc., Omaha

89123

Advanced Biomedical Research of America, Las Vegas

06611

New England Research Associates, Trumbull

16635-8406

Altoona Center for Clinical Research, Duncansville

All Listed Sponsors
lead

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT00626275 - Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Participants With Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter